Breaking News Instant updates and real-time market news.

VRX

Valeant

$13.59

-0.79 (-5.49%)

18:14
03/01/17
03/01
18:14
03/01/17
18:14

Valeant corrects 'erroneous' report about Salix investigation

Valeant Pharmaceutical said it "corrected an erroneous news report that mischaracterized the timing of the initiation of an SEC investigation disclosed in the company's Annual Report on Form 10-K for the year ended December 31, 2016, which was filed today." The SEC investigation into possible securities law violations by Salix was first disclosed by Valeant on April 30, 2015 in its Quarterly Report on Form 10-Q for the quarter ended March 31, 2015, and subsequently thereafter in its quarterly and annual filings. The disclosure in the company's Form 10-K filed today is identical to the disclosure included in the company's Form 10-Q filed on October 26, 2015. This investigation relates to legacy Salix matters that precede the acquisition of Salix by Valeant in April 2015.

  • 02

    Mar

  • 14

    Mar

VRX Valeant
$13.59

-0.79 (-5.49%)

02/28/17
WELS
02/28/17
NO CHANGE
WELS
Underperform
All Valeant franchises 'stagnating or in decline,' says Wells Fargo
In a post-earnings research note titled "Saying It Does Not Make It So," Wells Fargo analyst David Maris tells investors to review Valeant Pharmaceuticals' financial statement facts "very carefully." Valeant appears to claim victory in its earnings release by stating it has stabilized and strengthened its business, but its franchises "all appear to be stagnating or in decline and cash generation continues to deteriorate," Maris writes. He points out the company's adjusted EBITDA declined 20% in 2016 and 24% in Q4 relative to last year. Maris says his first look at the Q4 results indicate a worse than expected quarter. He keeps an Underperform rating on Valeant with a $10-$13 price target range. The stock in early trading is down 10%, or $1.75, to $14.96.
03/01/17
JPMS
03/01/17
NO CHANGE
Target $15
JPMS
Neutral
JPMorgan sees 'challenging' year for Valeant, cuts target to $15
After speaking with management following the Q4 earnings report, JPMorgan analyst Chris Schott believes 2017 will be a "challenging" year for Valeant Pharmaceuticals due to "significant" generic pressures, currency headwinds and the "negative drag" from announced divestitures. The analyst continues to see a "long road to recovery" for the Valeant story. He cut his price target for the shares to $15 from $22 after lowering again his 2017 estimates for sales, earnings and EBITDA. Schott keeps a Neutral rating on Valeant. The drugmaker closed yesterday down 14%, or $2.33, to $14.38 following its Q4 earnings report.
03/01/17
ADAM
03/01/17
NO CHANGE
Target $17
ADAM
Hold
Valeant guidance portends weaker outlook, says Canaccord
Canaccord analyst Neil Maruoka noted Valeant announced inline Q4 results and guidance that was below expectations. He believes the lowered guidance did not reflect the impact of recent divestitures, meaning guidance could be lowered further. Maruoka maintained his Hold rating and lowered his price target to $17 from $19 on Valeant shares.
03/01/17
BMOC
03/01/17
NO CHANGE
Target $19
BMOC
Market Perform
Valeant price target lowered to $19 from $21 at BMO Capital
BMO Capital analyst Gary Nachman noted that Valeant management struck a cautious tone along with its 2017 guidance and he lowered his estimates "meaningfully" in the wake of its report and outlook commentary. The analyst, who cut his price target on Valeant shares to $19 from $21, keeps a Market Perform rating on the stock, citing caution on its ability to accelerate debt paydown and the wait for improved execution.

TODAY'S FREE FLY STORIES

CDXS

Codexis

17:46
11/20/17
11/20
17:46
11/20/17
17:46
Hot Stocks
Breaking Hot Stocks news story on Codexis »

Telemark Asset Management…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

T

AT&T

$34.64

0.13 (0.38%)

, TWX

Time Warner

$87.71

-1.01 (-1.14%)

17:45
11/20/17
11/20
17:45
11/20/17
17:45
Hot Stocks
AT&T CEO says giving up control of CNN is a 'non-starter' »

Says plenty of solutions…

T

AT&T

$34.64

0.13 (0.38%)

TWX

Time Warner

$87.71

-1.01 (-1.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Nov

BBY

Best Buy

$56.35

0.52 (0.93%)

17:45
11/20/17
11/20
17:45
11/20/17
17:45
Conference/Events
Best Buy management to meet with SunTrust »

Group dinner to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 20

    Nov

  • 21

    Nov

T

AT&T

$34.64

0.13 (0.38%)

, TWX

Time Warner

$87.71

-1.01 (-1.14%)

17:43
11/20/17
11/20
17:43
11/20/17
17:43
Hot Stocks
AT&T CEO says DOJ suit 'defies logic' »

Says has offered…

T

AT&T

$34.64

0.13 (0.38%)

TWX

Time Warner

$87.71

-1.01 (-1.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Nov

RELY

Real Industry

$0.52

0.1643 (45.92%)

17:38
11/20/17
11/20
17:38
11/20/17
17:38
Hot Stocks
Real Industry, Real Alloy receive court approval of 'first day' motions »

Real Industry announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RAVN

Raven

$34.65

0.85 (2.51%)

17:34
11/20/17
11/20
17:34
11/20/17
17:34
Earnings
Raven reports Q3 EPS 33c, consensus 23c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

ONTX

Onconova

$1.70

0.01 (0.59%)

17:34
11/20/17
11/20
17:34
11/20/17
17:34
Syndicate
Breaking Syndicate news story on Onconova »

Onconova files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

ONTX

Onconova

$1.70

0.01 (0.59%)

17:33
11/20/17
11/20
17:33
11/20/17
17:33
Syndicate
Breaking Syndicate news story on Onconova »

Onconova files $84.55M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

MLNX

Mellanox

$51.05

1 (2.00%)

17:31
11/20/17
11/20
17:31
11/20/17
17:31
Hot Stocks
Starboard Value reports 9.8% stake in Mellanox »

Starboard has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 05

    Dec

  • 06

    Dec

ASYS

Amtech Systems

$14.12

0.93 (7.05%)

, PANW

Palo Alto Networks

$142.53

-0.19 (-0.13%)

17:27
11/20/17
11/20
17:27
11/20/17
17:27
Hot Stocks
On The Fly: After Hours Movers »

UP AFTER EARNINGS: Amtech…

ASYS

Amtech Systems

$14.12

0.93 (7.05%)

PANW

Palo Alto Networks

$142.53

-0.19 (-0.13%)

URBN

Urban Outfitters

$28.27

0.37 (1.33%)

CLSN

Celsion

$2.14

0.14 (7.00%)

SNSS

Sunesis

$2.87

0.01 (0.35%)

HAIN

Hain Celestial

$40.89

1.05 (2.64%)

NSRGY

Nestle

$85.14

0.03 (0.04%)

A

Agilent

$69.96

1.17 (1.70%)

BECN

Beacon Roofing

$56.28

0.65 (1.17%)

INTU

Intuit

$157.78

1.23 (0.79%)

SNCR

Synchronoss

$11.14

0.76 (7.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 30

    Nov

  • 11

    Dec

  • 11

    Dec

  • 17

    Jan

  • 17

    Jan

SNGX

Soligenix

$2.24

0.02 (0.90%)

17:23
11/20/17
11/20
17:23
11/20/17
17:23
Syndicate
Breaking Syndicate news story on Soligenix »

Soligenix files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTIB

CTI Industries

$3.56

-0.269 (-7.03%)

17:23
11/20/17
11/20
17:23
11/20/17
17:23
Hot Stocks
CTI Industries names Frank Cesario CFO »

CTI Industries announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SEDG

SolarEdge

$38.90

1.35 (3.60%)

17:22
11/20/17
11/20
17:22
11/20/17
17:22
Hot Stocks
SolarEdge chairman, CEO Sella diagnosed with colon cancer »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 28

    Nov

  • 29

    Nov

STLY

Stanley Furniture

$0.93

0.0349 (3.92%)

17:20
11/20/17
11/20
17:20
11/20/17
17:20
Hot Stocks
Breaking Hot Stocks news story on Stanley Furniture »

Stanley Furniture trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GLAD

Gladstone Capital

$9.76

-0.02 (-0.20%)

17:09
11/20/17
11/20
17:09
11/20/17
17:09
Earnings
Gladstone Capital reports Q4 NII 21c, consensus 21c »

Reports NAV per share…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

T

AT&T

$34.64

0.13 (0.38%)

, TWX

Time Warner

$87.71

-1.01 (-1.14%)

17:07
11/20/17
11/20
17:07
11/20/17
17:07
Hot Stocks
Breaking Hot Stocks news story on AT&T, Time Warner »

Department of Justice…

T

AT&T

$34.64

0.13 (0.38%)

TWX

Time Warner

$87.71

-1.01 (-1.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Nov

LMT

Lockheed Martin

$314.65

4.95 (1.60%)

17:07
11/20/17
11/20
17:07
11/20/17
17:07
Hot Stocks
Lockheed Martin awarded $122.3M U.S. Navy contract »

ockheed Martin Rotary and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

ZTO

ZTO Express

$17.00

0.17 (1.01%)

17:02
11/20/17
11/20
17:02
11/20/17
17:02
Earnings
Breaking Earnings news story on ZTO Express »

ZTO Express sees Q4…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

MSG

Madison Square Garden

$215.00

-3.46 (-1.58%)

17:01
11/20/17
11/20
17:01
11/20/17
17:01
Hot Stocks
Madison Square Garden acquires Obscura Digital, terms not disclosed »

The Madison Square Garden…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZTO

ZTO Express

$17.00

0.17 (1.01%)

17:01
11/20/17
11/20
17:01
11/20/17
17:01
Earnings
ZTO Express reports Q3 EPS 15c, consensus 15c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

VICL

Vical

$1.98

0.04 (2.06%)

16:59
11/20/17
11/20
16:59
11/20/17
16:59
Hot Stocks
Breaking Hot Stocks news story on Vical »

Armistice Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BECN

Beacon Roofing

$56.28

0.65 (1.17%)

16:57
11/20/17
11/20
16:57
11/20/17
16:57
Earnings
Beacon Roofing sees FY18 adjusted EPS $2.95-$3.25, consensus $2.57 »

Sees FY18 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

ABC

AmerisourceBergen

$77.46

-1.38 (-1.75%)

16:56
11/20/17
11/20
16:56
11/20/17
16:56
Earnings
AmerisourceBergen sees FY18 revenue up 8%-11% following H.D. Smith acquisition »

Consensus $164.76B. Based…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 29

    Nov

ABC

AmerisourceBergen

$77.46

-1.38 (-1.75%)

16:53
11/20/17
11/20
16:53
11/20/17
16:53
Hot Stocks
AmerisourceBergen to acquire H.D. Smith for $815M in cash »

AmerisourceBergen…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 29

    Nov

RGEN

Repligen

$33.26

-0.14 (-0.42%)

16:53
11/20/17
11/20
16:53
11/20/17
16:53
Conference/Events
Repligen management to meet with Stephens »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.